Literature DB >> 1985046

A rodent model of cirrhosis, ascites, and bacterial peritonitis.

B A Runyon1, S Sugano, G Kanel, M A Mellencamp.   

Abstract

We sought to develop a rodent model of spontaneous bacterial peritonitis and report here the preliminary results of carbon tetrachloride-induced cirrhosis in which ascites and bacterial peritonitis predictably develop. Of 41 rats that survived the initial carbon tetrachloride toxicity, 38 (92.7%) developed cirrhosis with ascites. Of these 38, 21 (55.3%) developed 24 episodes of ascitic fluid infection without iatrogenic colonization. No surgically treatable source of infection was identified at autopsy in any rat; therefore, the infections were presumed to be "spontaneous." Eight (50%) of the 16 rats with culture-positive ascitic fluid at postmortem examination also had spontaneous pleural fluid infection with the same organism. Escherichia coli and Proteus sp. were the organisms most commonly isolated. This rodent model of cirrhosis with ascites appears to be the first high-yield animal model of spontaneous bacterial peritonitis. Ascitic fluid infection in these rats resembles ascitic fluid infection in humans. This model will allow further investigation of the mechanisms of pathogenesis of ascitic fluid infection and provide insight into the prevention and treatment of spontaneous bacterial peritonitis and pleural fluid infection in patients with cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1985046     DOI: 10.1016/0016-5085(91)90221-6

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  12 in total

1.  Early events in spontaneous bacterial peritonitis.

Authors:  B A Runyon
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

2.  Effect of long-term trimethoprim-sulfamethoxazole prophylaxis on ascites formation, bacterial translocation, spontaneous bacterial peritonitis, and survival in cirrhotic rats.

Authors:  C Guarner; B A Runyon; M Heck; S Young; M Y Sheikh
Journal:  Dig Dis Sci       Date:  1999-10       Impact factor: 3.199

3.  The diagnostic value of neutrophil gelatinase-associated lipocalin and hepcidin in bacteria translocation of liver cirrhosis.

Authors:  Jiangguo Zhang; Fengyun Gong; Ling Li; Manzhi Zhao; Zhuhua Wu; Jianxin Song
Journal:  Int J Clin Exp Med       Date:  2015-09-15

4.  Endotoxin levels in cirrhotic rats with sterile and infected ascites.

Authors:  S Sugano
Journal:  Gastroenterol Jpn       Date:  1992-06

Review 5.  Spontaneous bacterial peritonitis.

Authors:  Anastasios Koulaouzidis; Shivaram Bhat; Athar A Saeed
Journal:  World J Gastroenterol       Date:  2009-03-07       Impact factor: 5.742

Review 6.  Spontaneous bacterial peritonitis in liver cirrhosis: treatment and prophylaxis.

Authors:  V Arroyo; M Navasa; A Rimola
Journal:  Infection       Date:  1994       Impact factor: 3.553

7.  Bacterial translocation in cirrhotic rats. Its role in the development of spontaneous bacterial peritonitis.

Authors:  J M Llovet; R Bartolí; R Planas; E Cabré; M Jimenez; A Urban; I Ojanguren; J Arnal; M A Gassull
Journal:  Gut       Date:  1994-11       Impact factor: 23.059

8.  Rifaximin, but not growth factor 1, reduces brain edema in cirrhotic rats.

Authors:  Gemma Odena; Mireia Miquel; Anna Serafín; Amparo Galan; Rosa Morillas; Ramon Planas; Ramon Bartolí
Journal:  World J Gastroenterol       Date:  2012-05-07       Impact factor: 5.742

9.  Testing beneficial therapy in human cirrhosis using animal models of cirrhosis.

Authors:  John Carl Hoefs; Timothy Morgan; Bernard Joseph Ilagan
Journal:  Dig Dis Sci       Date:  2011-04       Impact factor: 3.199

10.  Modulation of inflammatory response in a cirrhotic rat model with induced bacterial peritonitis.

Authors:  Elisabet Sánchez; Rubén Francés; Germán Soriano; Beatriz Mirelis; Francesc J Sancho; José Manuel González-Navajas; Carlos Muñoz; Xiao-yu Song; Miguel Pérez-Mateo; José Such; Carlos Guarner
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.